Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Cellular Biomedicine Starts China Trial of CAR-T Drug for Multiple Myeloma

publication date: Jan 9, 2019

Cellular Biomedicine, a Shanghai immunotherapy/stem cell company, has started a China trial of its anti-BCMA CAR-T therapy in patients with relapsed and refractory multiple myeloma. The Phase I trial will enroll 22 patients to evaluate the safety and efficacy of the candidate. In 2018, Novartis chose CBMG to be its China manufacturer of Kymriah®, an approved CAR-T therapy. Novartis invested $40 million in CBMG for a 9% stake in the company as part of the agreement. More details....

Stock Symbols: (NSDQ: CBMG) (NYSE: NVS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.